Sort
64,565 grants matching “drug discovery”
"Genetic and clinical studies of Gaucher disease and other lysosomal disorders"
$2,706,100Ellen Sidransky · National Human Genome Research Institute · ZIA · FY2019 · HG
Atherosclerosis Intervention with Novel Tissue Selective Estrogen Complex Therapy
$2,705,412Howard N Hodis · University Of Southern California · R01 · FY2020 · AG
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
$2,704,375Mark Thomas Gladwin · University Of Pittsburgh At Pittsburgh · P01 · FY2016 · HL
Rush Alzheimer's Disease Core Center
$2,702,350David A Bennett · Rush University Medical Center · P30 · FY2017 · AG
COG NCTN Network Group Operations Center
$2,702,029Richard Aplenc · Children'S Hosp Of Philadelphia · U10 · FY2020 · CA
Asthma Inflammation Research
$2,700,616Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru · P01 · FY2017 · HL
IGF::OT::IGF DISCOVERY OF NOVEL DRUG COMBINATIONS FOR CLINICAL DEVELOPMENT
$2,700,568Ralph Parchment · Leidos Biomedical Research, Inc. · N01 · FY2016 · CA
The Southwest Comprehensive Center for Drug Discovery and Development
$2,700,503Nathalie Meurice · Translational Genomics Research Inst · RC2 · FY2010 · MH
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
$2,700,395Mark Thomas Gladwin · University Of Pittsburgh At Pittsburgh · P01 · FY2017 · HL
Rush Alzheimer's Disease Core Center
$2,700,313David A Bennett · Rush University Medical Center · P30 · FY2016 · AG
Trans-synaptic bidirectional tracing tools for imaging and omics analysis
$2,700,173Alice Y Ting · Stanford University · RF1 · FY2018 · MH
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$2,700,161Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Collaborative Research: EPiQC: Enabling Practical-Scale Quantum Computation
$2,700,000Peter W Shor · Massachusetts Institute Of Technology · · FY2018 · CSE
Track-2: The Smart MATerial Design, Analysis, and Processing (SMATDAP) consortium: Building next-generation polymers and the tools to accelerate cost-effective commercial productio
$2,699,753John A Hamilton · Mississippi State University · · FY2014 · O/D
Novel Targeted Therapies for Pulmonary Fibrosis
$2,698,274Jan E Schnitzer · Proteogenomics Research Instit/Sys/ Med · P01 · FY2016 · HL
Novel Targeted Therapies for Pulmonary Fibrosis
$2,698,059Jan E Schnitzer · Proteogenomics Research Instit/Sys/ Med · P01 · FY2017 · HL
Novel Targeted Therapies for Pulmonary Fibrosis
$2,697,831Jan E Schnitzer · Proteogenomics Research Instit/Sys/ Med · P01 · FY2018 · HL
Novel Targeted Therapies for Pulmonary Fibrosis
$2,697,594Jan E Schnitzer · Proteogenomics Research Instit/Sys/ Med · P01 · FY2019 · HL
Development of small molecule-based methods for targeted cargo delivery to beta cells
$2,696,088Amit Choudhary · Broad Institute, Inc. · UC4 · FY2017 · DK
Genetic variant-based drug discovery targeting conserved pathways of aging
$2,694,643Jan No Middle Name Vijg · Albert Einstein College Of Medicine · U19 · FY2024 · AG
Integration, Dissemination and Evaluation(BRIDGE) Center for the NIH Bridge to Artificial Intelligence (BRIDGE2AI) Program
$2,692,667Monica Cecilia Munoz-Torres · University Of Colorado Denver · U54 · FY2022 · HG
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
$2,689,478Laura J Esserman · University Of California, San Francisco · P01 · FY2023 · CA
Program Project in Models of Breast Cancer
$2,686,001Larry Norton · Sloan-Kettering Inst Can Research · P01 · FY2006 · CA
Support for Enhancement Excellence in Research at UPR RP
$2,680,908University Of Puerto Rico Rio Piedras · S06 · FY2005 · GM
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
$2,680,161Lawrence R Toll · Phoenix Pharmalabs, Inc. · U01 · FY2022 · DA